Make a Better Place

Creating an ethical future and a healthier world through innovative non-clinical drug evaluation technologies.

NEXEL is a biotechnology company leading a new paradigm in the global non-clinical drug evaluation market, powered by our human induced pluripotent stem cell (hiPSC)-derived functional cell technologies.
Today, the global pharmaceutical and biotech industry is rapidly transitioning into an era of New Approach Methodologies (NAMs) to overcome the limitations of traditional animal testing and enhance clinical relevance. In line with these evolving demands, NEXEL has continuously driven technological innovation. In July 2026, we achieved a significant milestone by becoming the world’s first hiPSC-derived cardiomyocyte platform to enter the US FDA ISTAND program with LOI acceptance.
This achievement was made possible through our resolute determination and commitment to building a better world under our core management philosophy: “Make a Better Place.” Together with our dedicated team, NEXEL is steadily advancing toward our shared goals and growing into the most trusted non-clinical strategic partner in global drug development.
Moving forward, NEXEL will focus all of our capabilities on helping partners rapidly and accurately validate the safety and efficacy of new drug candidates.
We ask for your continued interest and support as we strive to build an ethical bio-ecosystem that reduces animal testing and advances healthy lives for humanity.

Thank you.

Choongseong Han
CEO, NEXEL Co., Ltd.